DUBLIN – Astrazeneca plc’s competitive efforts in type 2 diabetes, one of its key growth platforms, hit a setback when the FDA issued a complete response letter for its saxa/dapa combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.